← Eichor
Study identifier: NCT05535192 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

Condition: Breast Cancer · Stage III Breast Cancer · Breast Cancer Female  ·  Sponsor: Dana-Farber Cancer Institute

PhaseNA
Planned participants270
Who can joinFemale, 65 Years to no upper limit
Healthy volunteersNo

About this study

This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to schedule and at the planned dose.

This description comes directly from the study's public registry record.

Talk to the study team

Kathryn Schmitz, PhD, MPH  ·  412-623-6216  ·  schmitzk@upmc.edu

Jennifer Ligibel, MD  ·  617-632-3800  ·  jennifer_ligibel@dfci.harvard.edu

Always discuss trial participation with your own doctor first.

Locations (4)

Dana Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting
Case Western Reserve University/University Hospitals ClevelandCleveland, Ohio, United StatesRecruiting
University of PittsburghPittsburgh, Pennsylvania, United StatesRecruiting
Mount Nittany Medical CenterState College, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05535192